Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

François‐Xavier Mahon, Delphine Réa, Joëlle Guilhot et al. · The Lancet Oncology · 2010 · 1.5K citations

Medicine, Hematology, Pharmacology +4

Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia

Timothy P. Hughes, Jaspal Kaeda, Susan Branford et al. · New England Journal of Medicine · 2003 · 1.2K citations · Full text

Life Sciences, Hematology, Oncology +13

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

David M. Ross, Susan Branford, John F. Seymour et al. · Blood · 2013 · 706 citations

Medicine, Immunology, Pharmacotherapy +11

Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia

Jeffrey J. Molldrem, Peter P. Lee, Changqing Wang et al. · Nature Medicine · 2000 · 669 citations

Life Sciences, Immunology, Oncology +11

Hematologic Remission and Cytogenetic Improvement Induced by Recombinant Human Interferon Alpha_Ain Chronic Myelogenous Leukemia

Moshe Talpaz, Hagop M. Kantarjian, Kenneth B. McCredie et al. · New England Journal of Medicine · 1986 · 660 citations

Medicine, Hematology, Immunology +15